

from] of the MART-1 (melanoma antigen recognized by T-cells-1) amino acid sequence (Figure 1; SEQ ID NO: 2) or the gp100 amino acid sequence (Figure 5A; SEQ ID NO: 27), said peptide being [recognized by] capable of reacting with tumor infiltrating lymphocytes (TIL).

58. (amended) An [As] isolated nucleic acid sequence encoding a MART-1 (melanoma antigen recognized by T-cells-1) protein and having the nucleic acid sequence selected from the group consisting of: (a) a nucleic acid sequence shown in Figure 1 (SEQ ID NO:1); and (b) an allelic variation of the nucleic acid sequence shown in Figure 1 (SEQ ID NO:1)[; and (c) a homolog of the nucleic acid sequence shown in Figure 1 (SEQ ID NO:1)], wherein the nucleic acid sequences of (a) - (c) encode a melanoma antigen.

63. (amended) An isolated nucleic acid sequence encoding for a MART-1 (melanoma antigen recognized by T-cells) protein as set forth in Figure 1 (SEQ ID NO:2), wherein said nucleic acid sequence is substantially homologous [hybridizes] to the MART-1 nucleic acid sequence set forth in Figure 1 (SEQ ID NO:1) [under stringent conditions].

REMARKS

Applicants respectfully request reconsideration of the pending claims in view of the herewith presented remarks.

Claims 56-60 and 62-65 are pending in this application.